BACKGROUND: Previous studies have reported higher circulating bile acid levels in patients with HCC compared to healthy controls. However, the association between prediagnostic bile acid levels and HCC risk among patients with cirrhosis is unclear. METHODS: We measured total BA (TBA) concentration in serum samples collected from a prospective cohort of patients with cirrhosis who were followed until the development of HCC, death, or last study date. Competing risk proportional hazard-adjusted models were used to estimate the association between tertiles of serum TBA levels and the risk of developing HCC. We quantified the incremental predictive value of serum bile acid when added to a previously validated clinical model. RESULTS: We analyzed data from 940 patients with cirrhosis, of whom 68 patients progressed to HCC during 3406 person-years of follow-up. Higher baseline serum TBA level was significantly associated with an increased risk of developing HCC with an adjusted HR of 3.69 (95% CI = 1.85-7.37) for the highest versus lowest tertile. TBA levels significantly increased predictive ability for progression to HCC at 2 years of follow-up; the c statistic increased from 0.74 to 0.80 (p < 0.001). There was evidence for a significant interaction between TBA level and hepatitis C (p = 0.04). CONCLUSIONS: In a large prospective cohort study, the prediagnostic serum level of TBAs was associated with a significant increase in the risk of developing HCC among patients with multi-etiology cirrhosis. The TBA-associated risk was additive to that of established demographic and clinical predictors.
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis.
血清总胆汁酸水平与肝硬化患者发生肝细胞癌的风险增加有关
阅读:16
作者:El-Serag Hashem B, Thrift Aaron P, Duong Hao, Ning Jing, Khaderi Saira, Singal Amit G, Asrani Sumeet K, Marrero Jorge A, Powell Hannah, Rizwan Kinza, Najjar Omar, Amos Christopher I, Luster Michelle, Al-Sarraj Abeer, Salem Emad, Scheurer Michael E, Chhatwal Jagpreet, Kaochar Salma, Kanwal Fasiha
| 期刊: | Hepatology Communications | 影响因子: | 4.600 |
| 时间: | 2024 | 起止号: | 2024 Oct 10; 8(11):e0545 |
| doi: | 10.1097/HC9.0000000000000545 | 研究方向: | 细胞生物学 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
